Health and economic impact associated with a quadrivalent HPV vaccine in Italy

Gynecologic Oncology

Volumn 112, Issue 2, 2009, Pages 370-376

  Mennini, F S ^a   Giorgi Rossi, P ^b   Palazzo, F ^c   Largeron, N ^d  

^a Faculty of Science   (Italy)

^b Agency for Public Health   (Italy)

^c Istituto Di Ricerche Sulla Popolazione E Le Politiche Sociali Rome   (Italy)

^d SANOFI PASTEUR   (France)

Author keywords

Adolescents; Cervical cancer; Cost effectiveness analysis; Human papillomavirus; Italy; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ADULT; AGED; ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; FEMALE; HEALTH; HEALTH PROGRAM; HUMAN; ITALY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; UTERINE CERVIX CANCER; VACCINATION;

ADOLESCENT; ADULT; CHILD; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; ITALY; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 58249111475     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.09.031     Document Type: Article

References (63)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55 (2005) 74-108
2. World Health Organization. Technical information for policy markers and health professionals, WHO/IVB/07.05. Available at: http://www.who.int/vaccines-documents/DocsPDF07/866.pdf; 2007.
3. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189 1 (1999) 12-19
4. Koutsky L.A., Galloway D.A., and Holmes K.K. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 10 (1988) 122-163
5. Insinga R.P., Dasbach E.J., and Elbasha E.H. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics 23 (2005) 1107-1122
6. Clifford G.M., Smith J.S., Plummer M., and Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer 88 1 (2003) 63-73
7. Von Krogh G. Management of anogenital warts (condylomata acuminata). Eur. J. Dermatol. 11 6 (2001) 598-603
8. Ferlay J., Bray F., Pisani P., and Parkin D.M. Globocan 2002: Cancer incidence, mortality and prevalence worldwide. IARC cancer base no. 5, version 2.0 (2004), IARC Press, Lyon (France)
9. Istituto nazionale di statistica (ISTAT). La prevenzione dei tumori femminili in Italia; il ricorso a pap test e mammogragia: anni 2004-2005. Available at: http://www.istat.it/salastampa/comunicati/non_calendario/20061204_00/tes tointegrale.pdf; 2006.
10. Ricciardi A, Largeron N, Giorgi Rossi P, Raffaele M, Cohet C, Federici A, Palazzo F. Incidence of invasive cervical cancer and direct costs associated with its management in Italy. in press [Tumori].
11. Istituto nazionale di statistica (ISTAT) - Fattori di rischio e tutela della salute - Indagine multiscopo sulle famiglie italiane "Prevenzione dei tumori femminili: ricorso a pap test e mammografia" anni 2004/2005. Available at: http://www.istat.it/salastampa/comunicati/non_calendario/20061204_00/200 6; 2006.
12. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al., Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347 21 (2002) 1645-1651
13. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al., GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 364 9447 (2004) 1757-1765
14. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al., HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 367 9518 (2006) 1247-1255
15. Chesson H.W., Ekwueme D.U., Saraiya M., and Markowitz L.E. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg. Infect. Dis. 14 (2008) 244-251
16. Brisson M., Van de Velde N., De Wals P., and Boily M.C. Potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 25 29 (2007) 5399-5408
17. Kulasingam S.L., Benard S., Barnabas R., Largeron N., and Myers E.R. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis. Cost Eff. Resour. Alloc. 6 (2008) 4
18. Dasbach E, Insinga R, Elbasha E. Assessment of the health and economic impact of a Quadrivalent HPV vaccine in the United Kingdom using a transmission dynamic model. BJOG 2008. In press.
19. Szucs T.D., Largeron N., Dedes K.J., Rafia R., and Bénard S. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. Curr. Med. Res. Opin. 24 5 (2008) 1473-1483 May
20. Capri S., Bamfi F., and Marocco A. Impatto clinico ed economiuco della vaccinazione anti-HPV. Ital. J. Publich. Health Suppl 1 (2007) 59-85
21. Myers E.R., McCrory D.C., Nanda K., Bastian L., and Matchar D.B. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am. J. Epidemiol. 151 12 (2000) 1158-1171
22. Kulasingam S.L., and Myers E.R. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290 6 (2003) 781-789
23. ISTAT, Demografia in cifre. Available at: http://demo.istat.it.
24. Ronco G., Ghisetti V., Segnan N., Snijders P.J., Gillio-Tos A., Meijer C.J., et al. Prevalence of human papillomavirus infection in women in Turin, Italy. Eur. J. Cancer 41 2 (2005) 297-305
25. Italian Network of Cancer Registries Work Group. Italian cancer figures - report 2006. Incidence, mortality and estimates. Epidemiol. Prev. 30 (2006) 1-130
26. Kim J.J., Wright T.C., and Goldie S.J. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J. Natl. Cancer Inst. 97 12 (2005) 888-895
27. Materia E., Rossi L., Spadea T., Cacciani L., Baglio G., Cesaroni G., et al. Hysterectomy and socioeconomic position in Rome, Italy. J. Epidemiol. Community Health 56 6 (2002) 461-465
28. Coleman M.P., Gatta G., Verdecchia A., Estève J., Sant M., Storm H., et al. EUROCARE Working Group. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann. Oncol. 14 Suppl 5 (2003) v128-v149
29. WHO Statistical Information System (WHOSIS). Mortality database - Italy. Available at: http://www3.who.int/whosis/mort/table1_process.cfm; 2001.
30. Monsonego J., Breugelmans J.G., Bouee S., Lafuma A., Benard S., and Remy V. Incidence, prise en charge et coût des condylomes acumines anogénitaux chez les femmes consultant leur gynécologue en France. Gynecol. Obstet. Fertil. 35 2 (2007) 107-113
31. Insinga R.P., Glass A.G., Myers E.R., and Rush B.B. Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med. Decis. Mak. 27 (2007) 414-422
32. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al., Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. The New England Journal of Medicine 356 19 (2007) 1928-1943
33. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356 19 (2007) 1915-1927
34. Olsson S.-E., Villa L.L., and Costa R.y.c. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25 (2007) 4931-4939
35. Elbasha E.H., Dasbach E.J., and Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerging Infectious Disease 13 (2007) 28-41
36. Ronco G., Giubilato P., Naldoni C., Zorzi M., Anghinoni E., Scalisi A., et al. Activity level and process indicators of organised programmes for cervical cancer screening in Italy. Epidemiol. Prev. 30 suppl 3 (2006) 27-40
37. Regione Emilia Romagna (RER). Protocollo diagnostico-terapeutico dello screening per la prevenzione dei tumori del collo dell'utero nella regione (2004), Emilia-Romagna, Bologna
38. Società Italiana di Colposcopia e Patologia Cervico-Vaginale (SICPCV). Gestione della paziente con pap test anormale Linee Guida Edizione 2006. Available at:. http://www.colposcopiaitaliana.it/pdf07/Linee-Guida-2006.pdf last access April 24th 2008
39. Hospital information system, Lazio Region 2007. Available at: http://www.asplazio.it/asp_online/att_ospedaliera/sio_newr/sio_index.php ?menu=s21, last access April 24th 2008.
40. Ministero della salute. Nomenclatore delle prestazioni di assistenza specialistica. Available at: http://www.ministerosalute.it/resources/static/news/880/ultimo_corretta_ finanziaria_specialistica.pdf, last access April 24th 2008.
41. Merito M., Largeron N., Cohet C., et al. Treatment patterns and associated costs for genital warts in Italy. Curr Med Res Opin (2008 [Oct 10])
42. Azzari C., Massai C., Poggiolesi C., Indolfi G., Spagnolo G., De Luca M., et al. Cost of varicella-related hospitalizations in an Italian paediatric hospital: comparison with possible vaccination expenses. Current Medical Research and Opinion 23 12 (2007) 2945-2954
43. Coudeville L., Brunot A., Giaquinto C., Lucioni C., and Dervaux B. Varicella vaccination in Italy: an economic evaluation of different scenarios. Pharmacoeconomics 22 13 (2004) 839-855
44. Bonneux L., and Birnie E. The discount rate in the economic evaluation of prevention: a thought experiment. J. Epidemiol. Community Health 55 2 (2001) 123-125
45. Bos J.M., Postma M.J., and Annemans L. Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics 23 7 (2005) 639-649
46. Beutels P., Edmunds W.J., Antoñanzas F., De Wit G.A., Evans D., Feilden R., et al., Viral Hepatitis Prevention Board. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics 20 1 (2002) 1-7
47. Torgerson D.J., and Raftery J. Economic notes. Discounting. BMJ 319 7214 (1999) 914-915
48. Villa L, Villa L. The FUTURE I and II study group; Quadrivalent human papillomavirus (HPV) type 6,11,16,18 L1 virus-like particle vaccine: an analysis of cross-protection against cervical intraepithelial neoplasia caused by non-vaccine types: oral presentation. EUROGIN. 2-4 October 2007-Monte-Carlo-Monaco; 2007.
49. Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer 111 (2007) 145-153
50. Haupt RM. GARDASIL update. 2007 CDC Cancer Conference Program of Events; 2007 Aug 13-17; Atlanta. Atlanta: Centers for Disease Control and Prevention.
51. Franco E.L., and Ferenczy A. Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination. Future Oncol. 3 3 (2007) 319-327
52. Jit M., Choi Y.H., and Edmunds W.J. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 17 (2008) 337-a769
53. Goldhaber-Fiebert J.D., Stout N.K., Salomon J.A., Kuntz K.M., and Goldie S.J. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J. Natl. Cancer Inst. 100 (2008) 308-320
54. Canfell K., Barnabas R., Patnick J., and Beral V. The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br. J. Cancer 91 3 (2004) 530-536
55. Siebert U., Sroczynski G., and Hillemanns P. The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany. European Journal of Public Health 16 2 (2006) 185-192
56. Nanda K., McCrory D.C., Myers E.R., Bastian L.A., Hasselblad V., Hickey J.D., et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann. Intern. Med. 132 10 (2000) 810-819
57. Arbyn M., Buntinx F., Van Ranst M., Paraskevaidis E., Martin-Hirsch P., and Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J. Natl. Cancer Inst. 96 4 (2004) 280-293
58. Mitchell M.F., Schottenfeld D., Tortolero-Luna G., Cantor S.B., and Richards-Kortum R. Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet. Gynecol. 91 4 (1998) 626-631
59. Karnon J., Peters J., Platt J., Chilcott J., McGoogan E., and Brewer N. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. Health Technol. Assess. 8 20 (2004) iii,1-iii,78
60. Giorgi Rossi P., Largeron N., Cohet C., Palazzo F., Mennini F.S., Furnari G., et al. Impact and cost of the cervical cancer screening prevention in Italy (2007), HTAi, Barcelona, Spain
61. Bergeron B., Largeron N., Mcallister M., Mathevet M., and Remy R. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int. J. Technol. Assess Health Care 24 (2008) 10-19
62. Myers ER, Green S, Lipkus I. Patient preferences for health states related to HPV infection: visual analogue scales vs time trade-off elicitation. Proceedings of the 21st International Papillomavirus Conference Mexico City, Mexico 2004.
63. Goldie S.J., Kohli M., Grima D., Weinstein M.C., Wright T.C., Bosch F.X., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J. Natl. Cancer Inst. 96 8 (2004) 604-615